Navigation Links
KV Pharmaceutical Receives Permission from NYSE for its Securities to Continue Trading on the NYSE until March 31, 2010
Date:12/22/2009

ST. LOUIS, Dec. 22 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company ( KVa/KVb) (the "Company") received permission from the New York Stock Exchange (the "Exchange") for its securities to continue to trade on the Exchange until March 31, 2010 while the Company prepares its Annual Report on Form 10-K for the Company's fiscal year ended March 31, 2009 (the "2009 Annual Report").

In the event the Company is unable to file the 2009 Annual Report on or prior to March 31, 2010, the Company may request that the Exchange permit the Company's securities to continue to trade on the Exchange until June 17, 2010. In the event the Company is unable to file the 2009 Annual Report prior to June 17, 2010 (or prior to March 31, 2010 in the event the Company requests that the Exchange permit the Company's security to continue to trade on the Exchange until June 17, 2010 and such request is not granted by the Exchange), the Exchange will initiate suspension and delisting procedures.

As previously disclosed by the Company on its Form 12b-25 filed with the SEC on June 2, 2009, as well as in subsequent filings with the SEC, the Company has been unable to file its 2009 Annual Report. The Company's Current Report on Form 8-K filed with the SEC on November 12, 2009 sets forth additional information regarding the Company's inability to timely file the 2009 Annual Report, certain other periodic reports, and related matters.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a subsidiary that competes with branded products, and Ther-Rx Corporation, the company's branded drug subsidiary.

For further information about KV
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
7. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
8. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
9. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
10. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
11. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... 28, 2015 Recent Highlights: ... first patient in PerClot ® IDE ... device and tissue processing company focused on cardiac and ... quarter of 2015.  Pat Mackin, Chairman, ... significant milestones regarding two of our top organizational objectives.  ...
(Date:4/28/2015)... BERLIN , April 28, 2015 ... universities of Berlin and the ... Berlin as a central research location ... of scientific, technical and medical information products and services, ... Charité, the Humboldt University (Humboldt-Universität), the Free University ...
(Date:4/28/2015)... 28, 2015  Influential proxy advisory firm Institutional ... at Gilead Sciences, a shareholder proposal asking the ... management and mitigation of the business risks associated ... of rapidly increasing U.S. drug prices and efforts ... costs. Proposal 8, Stockholder ...
Breaking Medicine Technology:CryoLife Reports First Quarter Results 2CryoLife Reports First Quarter Results 3CryoLife Reports First Quarter Results 4CryoLife Reports First Quarter Results 5CryoLife Reports First Quarter Results 6CryoLife Reports First Quarter Results 7CryoLife Reports First Quarter Results 8CryoLife Reports First Quarter Results 9Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 2Elsevier and the Friedrich-Althoff Consortium Collaborate to Create "Archive of Berlin" as a Basis for a Common Research Infrastructure 3ISS Recommends Shareholders Vote For Specialty Drug Pricing Risk Assessment Proposal At Gilead Sciences 2ISS Recommends Shareholders Vote For Specialty Drug Pricing Risk Assessment Proposal At Gilead Sciences 3
(Date:4/28/2015)... Petersburg, FL (PRWEB) April 28, 2015 ... Health System were named to Becker's Hospital Review’s ... Safety . Peter Pronovost, M.D., Ph.D. , director ... Quality and senior vice president for patient safety ... Mueller, M.D., M.H.C.M. , vice president of medical affairs ...
(Date:4/28/2015)... 2015 The popular all-natural supplement brand, ... their newly launched L-Style Revolution Program™, and collectively the ... in just two short months. The customized weight ... plan for men and women of all health and ... and weight maintenance goals faster than traditional methods. , ...
(Date:4/28/2015)... (PRWEB) April 28, 2015 An ... Blair A. Jobe, MD, FACS , has launched the ... tissue with extracellular matrix (ECM) can help patients who ... of esophageal cancer. , ECM is a complex mixture ... attachment and migration and signals that guide cell behavior. ...
(Date:4/28/2015)... As the Muscular Dystrophy Association continues ... the organization has hired Scientific Program Officer Lianna ... Fidelity Biosciences Research Initiative where, as Associate Director, ... diseases such as Alzheimer’s Disease, and organized and ... Fidelity, she was a junior faculty member at ...
(Date:4/28/2015)... 28, 2015 Researchers from four US ... of a steroid prior to pemetrexed (Alimta) chemotherapy may ... Click here to read the full story ... the Raabe College of Pharmacy in Ohio, Stanford Cancer ... Regional Healthcare in Kentucky gave a single dose of ...
Breaking Medicine News(10 mins):Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 2Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 3Health News:Johns Hopkins Medicine and All Children’s Hospital Leaders Recognized as Top Experts in Patient Safety 4Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 2Health News:Sports Nutrition Supplement Brand, Liporidex, Is Making History With Its New L-Style Revolution Diet & Exercise Program Reaching Over 10,000 Pounds Lost In Two Months 3Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 2Health News:Allegheny Health Network Launches First U.S. Clinical Trial of Extracellular Matrix as Replacement for Pre-Cancerous Tissue 3Health News:MDA Adds Neurological Disease Expert to Research Team 2Health News:MDA Adds Neurological Disease Expert to Research Team 3Health News:Study Finds New Regimen May Ward Off Skin Rash from Common Mesothelioma Drug, According to Surviving Mesothelioma 2
... Jersey has its share of underserved children, according to a ... state,s children between 3 and 18 received no dental care ... almost one-third of the state,s children received no care, the ... were still likely to forgo visits to the dentist. ...
... EDITOR,S PICK: Predicting resistance to brain tumor chemotherapy ... lethal of all human brain tumors that originate in ... by both radiation therapy and chemotherapy with temozolomide. However, ... A team of researchers led by Sameer Agnihotri, at ...
... Medicine (BUSM) have identified for the first time the ... target against atherosclerosis resulting from a diet high in ... Circulation , may have significant public health implications. ... at low levels, and at higher levels during exercise ...
... have discovered how malaria manipulates the immune system to allow ... immune system pathway, the research team was able to cure ... published Dec. 11 in the Advance Online Publication of the ... a new approach for treating malaria that does not rely ...
... seedlings is important to crop growth and yield after ... stems, thick leaves, dark green leaves, and large white ... physiology are strongly influenced by the light spectrum, which ... has been shown to increase crop yield after planting ...
... December 11, 2011) Lymphoma and myeloma are both ... blood cells, and commonly involve lymph nodes and the ... the treatment of these diseases, they remain a significant ... unique treatment approaches and targets for lymphoma and myeloma ...
Cached Medicine News:Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 2Health News:Rutgers Study: When it comes to use of dental services, not all NJ youngsters are equal 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:Researchers identify agent responsible for protection against early stages of atherosclerosis 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 2Health News:Researchers use new finding to clear bloodstream malaria infection in mice 3Health News:Blue light irradiation promotes growth, increases antioxidants in lettuce seedlings 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 2Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 3Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 4Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 5Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 6Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 7Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 8Health News:Emerging lymphoma and myeloma treatments focus on improving individual patient response 9
... Jenner Stain is used for ... is one of the oldest stain ... provides results similar to that of ... to appear brighter red; basophilic granules ...
Our Reticulocyte Stain is a specialized hematology stain for identifying immature erythrocytes. These immature erythrocytes stain blue in a fine mesh network within the erythrocyte. Mature erythrocyt...
The Buffered Wright Stain is a single solution stain that contains the fixative, buffer, and stain for rapid and convenient staining of blood smears. It is packaged in a 32-oz. bottle for ease of use...
Our Wright stain is a dual-use stain for peripheral blood and bone marrow smears. It produces results similar to those of the Giemsa stain with a slightly greater contrast....
Medicine Products: